3 completed. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
Follow Stalevo: new trials by email Literature Review of Stalevo trials Research Report on Stalevo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Wearing-off (COMPOC) Stalevo, levodopa MR - Parkinson's Disease | Phase 2 | Completed | Orion Corporation, Orion Pharma | 84 | 2016-04-08 | 2018-04-05 |
| Efficacy and Safety Proof of Concept Study in Patients With Parkinson's Disease and End-of-dose Motor Fluctuations ODM-101 65mg Carbidopa, ODM-101 105mg Carbidopa, Stalevo - Parkinson's Disease | Phase 2 | Completed | Orion Corporation, Orion Pharma | 117 | 2011-05-01 | 2013-11-21 |
| An Open-Label Feasibility/Pilot Study With [123I]-IBZM SPECT (DOPA-SYN) carbidopa/l-dopa, carbidopa/l-dopa/entacapone, Stalevo - Parkinson's Disease | Phase 2 | Completed | Molecular NeuroImaging | 3 | 2004-03-01 | 2008-01-21 |
Orion Corporation, Orion Pharma (2) · Molecular NeuroImaging (1)
Finland (1) · Germany (1) · Hungary (1) · Latvia (1)
Aila Holopainen, MSc (1) · Claudia Trenkwalder, MD (1) · John P Seibyl, MD (1)